Objective: The current study examined the effects of pharmacologic dopaminergic manipulations on working memory-related brain activation in postmenopausal women to further understand the neurochemistry underlying cognition after menopause.
T he brain is a major target for circulating gonadal steroids, and the change in hormone levels after menopause is likely to have implications for cognitive functioning. Clinical and preclinical studies have linked gonadal steroids and cognition, 1, 2 and it has been hypothesized that menopause has detrimental effects on cognition that are over and above the expected effects of normal aging. Evidence for changes in cognition after menopause is, however, equivocal. Some studies found decreased cognitive performance postmenopause in domains such as memory, attention, problem solving, and motor skills. [3] [4] [5] Other studies have not found changes in cognition postmenopause. [6] [7] [8] One way to begin to understand these individual differences in cognition postmenopause is to examine the underlying neurobiological processes that are affected by menopause.
Subjective reports of changes in executive functioning at midlife are a concern for many women. Studies have shown as many as 60% of women reported undesirable memory changes at midlife. 9 One mechanism hypothesized to be responsible for cognitive changes postmenopause is the decrease in estradiol and its effects on the functioning of the prefrontal cortex. 10 In addition, the estradiol change postmenopause has been shown to affect the functioning of neurotransmitter systems in the prefrontal cortex that support cognition across a number of model systems from rats 2 to nonhuman primates 11 to humans. 12 Particular focus has been given to executive functioning changes after menopause, and one component that is often examined is working memory. 13 Working memory is the ability to hold and manipulate a small amount of information over a short period of time.
14 Longitudinal studies of cognition as women move across the menopausal transition indicate that working memory is not impaired by menopause. 1, 3 Studies have shown that working memory was improved by postmenopausal estrogen. 15, 16 Thus, working memory systems are modifiable in postmenopausal women.
Working memory is also modulated by dopaminergic systems through the frontal-striatal pathway, 17 and it has been hypothesized that age changes in the frontal lobe dopaminergic system are responsible for cognitive aging. 18 Studies have shown that there is a linear age-related decrease in dopamine receptor availability. 19, 20 In addition, there are sex differences in D 2 receptor binding particularly in the frontal cortex, 19 with one study showing greater binding for women than men, 21 thus implicating a role for gonadal steroid modulation of dopaminergic functioning.
A handful of prior studies have examined dopaminergic functioning in postmenopausal women. Craig et al 22 found that long-term postmenopausal estrogen treatment enhanced dopaminergic responsivity as measured by the growth hormone response to apomorphine challenge compared with women not taking estrogen therapy. Gardiner et al 23 found an increase in dopamine transporter relative to baseline in the putamen in women who took 0.625 mg oral conjugated equine estrogen per day for 4 weeks and then another 2 weeks of conjugated equine estrogen plus 10 mg oral medroxyprogesterone acetate. Epperson et al 24 examined the effects of atomoxetine, a selective norepinephrine reuptake inhibitor that increases extracellular norepinephrine and dopamine, in peri-and postmenopausal women with subjective cognitive complaints. They found that peri-and postmenopausal women showed improvement in subjective but not objective cognition after atomoxetine compared with placebo (PLC).
The prior literature shows that dopaminergic systems remain responsive in postmenopausal women and are involved in cognitive processes that are affected by estrogen. [22] [23] [24] It is, however, difficult to isolate the contribution of the dopaminergic system independent of estrogen treatment or norepinephrine modulation in the studies. The current study examined direct stimulation and blockade of the dopaminergic system in healthy postmenopausal women during a functional magnetic resonance imaging (fMRI) working memory task. Working memory tasks during fMRI activate a network of bilateral frontal, parietal, and cerebellar regions. 25 In postmenopausal women, estrogen treatment compared with PLC has been shown to increase frontal activation during working memory tasks. 26, 27 Studies in younger adults have shown frontal lobe modulation of working memory networks after dopaminergic manipulations, 28, 29 and decreased frontal activation was observed when performance was improved suggesting increased dopaminergic efficiency. No studies thus far have examined dopaminergic manipulations in postmenopausal women during an fMRI working memory task to examine the direct influence of dopaminergic modulation on working memory networks.
The aim of the study was to examine the independent contribution of direct dopaminergic manipulations on brain functioning in postmenopausal women. As much of the literature reviewed above examined estrogendopamine interactions after menopause, it is important to understand the independent dopaminergic contribution. We hypothesized that dopaminergic stimulation would increase frontal activation in the working memory network and improve working memory performance compared with dopaminergic blockade.
METHODS

Participants
Participants were 18 cognitively normal postmenopausal women, aged 52 to 59 years, M (SD) ¼ 55.21 (2.3; see Table 1 for demographic information). Sixteen participants were STRAWþ10 Stage þ1 early postmenopause and two were Stage þ2 late postmenopause based on their years since their final menstrual period. Participants were recruited with media advertisements in the Burlington, VT region. Four additional participants passed the screening, but withdrew before beginning the study days because of the time commitment for the study. Participants were required to be postmenopausal, without menses for 1 year and without surgically induced menopause. Medical exclusion criteria were similar to our prior studies 30 and included smoking, a history of breast cancer, use of hormone therapy during the last year, medications that have central nervous system effects, known intolerance to ergots, and contraindications for MRI. All participants met these criteria. None of the participants had a prior history of postmenopausal hormone use. Medication use by women in this study was as follows: two women took medications for hypertension, two took cholesterol lowering medications, two took levothyroxine for hypothyroidism, and three reported taking migraine medication as needed but not 48 hours before any study day.
After passing the telephone screening, participants came to the University of Vermont (UVM) Clinical Research Center (CRC) for a medical and psychological screening. As in our prior medication challenge studies, 12, 30 after signing informed consent documents, participants provided a medical history, underwent physical and laboratory tests assessing hematopoietic, renal, hepatic, and hormonal function. No women had any major medical illness as confirmed by the physical examination. Participants provided a blood sample that was used to ensure postmenopause status of follicle-stimulating hormone greater than 20 IU/L. Participants were cognitively evaluated using the Mini Mental State Exam, 31 Brief Cognitive Rating Scale, 32 and the Mattis Dementia Rating Scale (DRS 33 ) to establish a Global Deterioration Scale (GDS) score which rated the degree of cognitive impairment. 32 Participants were required to have a Mini Mental State Exam score greater than or equal to 27, a Dementia Rating Scale 
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score greater than or equal to 123, and a Global Deterioration Scale score of 1 or 2.
Behavioral screening consisted of a partial Structured Clinical Interview for DSM-IV-TR (SCID 34 ) to establish the presence/absence of major depression, mania, or dysthymia. Participants were also screened with the Beck Depression Inventory-II (BDI-II 35 ) . A cutoff score of 10 was used for the BDI, and participants scoring over this criterion were discontinued from further participation. Five out of 18 women had remitted major depressive disorder, and no women had current major depressive disorder. All participants met these criteria for the cognitive and behavioral screening.
Challenge procedure
After passing the medical and psychological screening, participants came to the UVM CRC for three dopaminergic challenge days. The medication on 1 day was the agonist bromocriptine (BROMO), on a second day it was the dopaminergic antagonist haloperidol (HAL), and the third day was PLC. On each challenge day, participants reported to the UVM CRC by 0700 (see Fig. 1 ). Similar to our prior medication challenge studies, 12, 30 each woman performed a baseline motor skill sobriety test to serve as a comparison to a second test before discharge in the afternoon. An intravenous line was inserted and blood was drawn for estradiol, estrone, and testosterone assays. At the end of the study, all assays were run in one batch for a radioimmunoassay at the Reproductive Endocrine Research Laboratory at the University of Southern California.
A double-blind, double-dummy method of administration of the challenge drugs was followed. Participants received 1.25 mg BROMO orally, 1.5 mg HAL orally, or matching oral PLC. Participants took one pill 180 minutes before the MRI examination that was either HAL or PLC. Then at 120 minutes before the MRI they took another pill that was either BROMO or PLC. On each day only one of the pills was active drug or both pills were PLC. Thus, one study day was BROMO challenge, 1 day was HAL challenge, and 1 day was PLC. These times are similar to what has been shown for BROMO 36 and HAL 37 to have their maximal effects on cognition. The half-life of BROMO has been shown to be 4.85 hours, and oral HAL is between 14 and 36 hours. Thus, study days occurred at least 1 week apart. Drug order was fully counterbalanced across participants. The drug order was developed by the CRC Informaticist and delivered directly to the research pharmacy so that study personnel remained blinded to drug order. Nausea was reported in 10% of our participants, but it occurred after the MRI session and did not impact data collection. After the fMRI session that took approximately 70 minutes, participants were given lunch. Vital signs and pupil diameter were assessed at six time points during the study day. At the end of the study day, participants were discharged after passing the sobriety test to the satisfaction of the research nurse and covering physician.
fMRI working memory task
The fMRI task was our standard 30, 38 visually presented verbal N-back task to probe working memory circuitry. Participants saw a string of consonants (except L, W, and Y), presented in upper case letters, one every 3 seconds. Four conditions were presented: 0-back, 1-back, 2-back, and 3-back. The 0-back control condition had a minimal working memory load; participants were asked to decide if the current letter matched a single target letter that was specified before the epoch began. In the 1-, 2-, and 3-back conditions, participants indicated whether the current letter on the screen matched a letter that was either 1, 2, or 3 back in the sequence.
The 0-, 1-, 2-, and 3-back conditions were repeated three times in a counterbalanced order such that the same condition was not repeated two times in a row. In this block design task, participants responded to nine items in each block that took 27 seconds. A rest break followed with a plus sign (þ) fixation for 12 seconds. The total time of the task was 8 minutes 12 seconds. Participants practiced the N-back task before drug dosing began on each challenge day to ensure that they understood task instructions.
Participants responded to all items indicating whether it was a match or mismatch by pressing a button on an MRI compatible fiber optic button response system (Psychology Software Tools, Pittsburgh, PA). Stimuli were delivered through an MR-safe computer monitor. Experimental tasks were programmed using the E-prime software package and presented by PC; the PC recorded participant responses.
Behavioral measures
At the beginning of each challenge day, participants completed the Profile of Mood States (POMS 39 ), BDI-II, 35 and Beck Anxiety Inventory 40 to obtain a baseline measure of mood before the testing procedures began. After the cognitive battery was completed, participants completed the POMS a second time as well as the Stanford Sleepiness Scale, 41 Subjective Visual Analogue Scale, 42 and a Physical Symptom Checklist. The experimenter completed the Brief Psychiatric Rating Scale 43 and Objective Visual Analogue Scale. 
DOPAMINE AND WORKING MEMORY POSTMENOPAUSE
fMRI scan procedure The MRI procedures were similar to our prior studies in postmenopausal women. 30, 38 All participants were scanned on a Philips 3T Achieva scanner and received the following MR sequences as part of the imaging protocol: (1) a sagittal T1-weighted spoiled gradient volumetric sequence oriented perpendicular to the anterior commissure (AC)-posterior commissure (PC) plane using a repetition time (TR) of 9.9 ms, echo time (TE) of 4.6 ms, flip angle of 88, number signal averages (NSA) 1, field of view (FOV) of 256 mm, 256 Â 256 matrix, and 1-mm slice thickness with no gap for 140 contiguous slices. (2) An axial T2-weighted gradient spin echo sequence using the AC-PC line for slice positioning. Twenty-eight contiguous slices 5 mm thick and no gap were acquired using TR 2,466 ms, TE 80 ms, NSA 3, and FOV of 230 mm. All images were reviewed by a board-certified neuroradiologist to exclude intracranial pathology. fMRI was performed using echoplanar blood-oxygen-level dependent (EpiBOLD) imaging using a single-shot sequence (TR 2,500 ms, TE 35 ms, flip angle 908, 1 NSA for 197 volumes). Resolution was 2.5 mm Â 2.8 mm Â 4 mm. Thirty-four contiguous slices 4 mm thick with no gap were obtained in the axial oblique plane parallel to the AC-PC plane using an FOV of 240 mm and a matrix size of 128 Â 96. Field map correction for magnetic inhomogeneities was accomplished by acquiring images with offset TE at the end of the functional series.
fMRI analyses
Statistical analyses were performed using a 3 (drug: BROMO, HAL, PLC) Â 4 (working memory load: 0-, 1-, 2-, 3-back) random effects ANOVA using standard ANOVA procedures in Brain Voyager (Brain Voyager QX, The Netherlands). We hypothesized that drug effects on working memory-related activation would increase as the working memory load increased; thus, the design matrix included all N-back conditions. The contrast vector for the overall interaction was as follows: À6, þ1, þ2, þ3 for the 0-, 1-, 2-, and 3-back conditions for the BROMO challenge day, þ6, À1, À2, À3 for the 0-, 1-, 2-, and 3-back conditions for the HAL challenge day, and 0, 0, 0, 0 for the PLC challenge day. This contrast allowed for the comparison of BROMO and HAL while including PLC information in the model. The hemodynamic response function was accounted for in these models. To probe the basis for the interaction between drug and working memory load, we examined drug effects in the following comparisons: 3-back minus 0-back, 2-back minus 0-back, and 1-back minus 0-back conditions. To examine the main effect of drug, we examined each drug compared to PLC across the increasing working memory load.
To correct for multiple comparisons, we used the clusterlevel statistical threshold estimator from Brain Voyager QX to estimate a minimal cluster size threshold based on the approach of Forman et al. 44 This procedure estimated a minimal cluster size of nine voxels in functional space (3 Â 3 Â 3) at an a level of 0.005 for the fMRI analyses described below.
Working memory performance analysis
Working memory performance during the N-back task was examined using the signal detection measures of sensitivity (d') and bias (C) 45 as we have done in our prior studies. 30, 38 Sensitivity is a measure of how different two classes of items are as measured by d' and is represented in SD units. In the Nback task, the two classes of items are matches and mismatches for each of the working memory load conditions. Larger d's represent greater sensitivity and greater accuracy. Bias (C) is the tendency for a participant to endorse a letter as a match or mismatch also represented in SD units. Liberal response bias indicates that a participant calls a large number of responses matches in contrast to conservative bias indicating that the participant makes many mismatch responses. Bias scores of greater than 0 are conservative, whereas bias scores less than 0 are liberal.
RESULTS
Activation data
First, we examined working memory-related brain activation during the N-back task to demonstrate the expected task effect on the PLC challenge day. Second, we examined the dopaminergic modulation of the working memory network after the BROMO compared with the HAL challenge day.
Working memory activation
In our sample of healthy postmenopausal women, when we examined the activation related to increasing working memory load, we found the expected bilateral frontal, parietal, and cerebellar working memory network on the PLC challenge day (Fig. 2) .
46,47
Dopaminergic modulation of working memory activation
Second, we examined brain activation for the effects of the dopaminergic manipulations on increasing working memory load during the N-back task. Specifically, we examined BROMO minus HAL as working memory load increased (Fig. 3) . Increased activation for BROMO compared with HAL was found in the left precentral gyrus (BA 6), and bilateral inferior parietal lobules (BA 40; Table 2 ).
To probe this interaction and further understand how the drug effects changed as the working memory load increased, we examined drug differences at each of the working memory load condition minus the 0-back match condition. First, for the 3-back minus 0-back comparison, greater activation was seen for the BROMO minus HAL comparison in regions similar to the activation observed for the overall interaction (Table 2) . Specifically, increased activation was seen in the left precentral gyrus (BA 6 and 3). Second, similar regions also showed increased activation for BROMO minus HAL comparison on the 2-back minus 0-back comparison in the left precentral gyrus (BA 4) and the left and right inferior parietal lobules (BA 40). Finally, for 1-back compared with the 0-back condition no activation differences were seen across challenge conditions.
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To examine the drug effect, we compared BROMO with PLC and HAL with PLC separately. The results showed increased activation for the BROMO minus PLC condition that were similar to the whole model in the left precentral gyrus and bilateral inferior parietal lobes. The HAL compared with PLC showed no differences at the alpha level used.
Working memory performance
Data were analyzed with a 3 (drug: BROMO, HAL, PLC) Â 4 (working memory load: 0-, 1-, 2-, 3-back) mixed model ANOVA for d', proportion correct, and C (Fig. 4A-C) . Challenge drug and working memory load were within-subjects factors.
The analysis of d' showed a main effect of working memory load (F(3,48) ¼ 478.62, P < 0.001). Performance was best on the 0-back and worst on the 2-back condition. There was no main effect or interaction involving challenge drug (Ps > 0.36). The data pattern for the percent correct measure was similar with a main effect of working memory load (F(3,48) ¼ 48.08, P < 0.001).
For the bias measure C, there was also a main effect of working memory load (F(3,48) ¼ 14.00, P < 0.001) that showed that as the working memory load increases participants became more conservative with their responding. There was no main effect or interaction involving drugs for the bias measure C.
Behavioral measures
At the beginning of each study day, participants completed the POMS, BDI, and Beck Anxiety Inventory questionnaires. There were no differences on mood ratings on these measures before each of the study days began (Ps > 0.14). Mood and physical symptoms were assessed after the MRI when participants returned to the CRC to examine the effects of the challenge drugs on mood and physical symptoms. No differences were found between the BROMO, HAL, and PLC study days on any of these measures.
Vital signs and hormone values
Blood pressure, pulse, and pupil diameter were monitored at six time points throughout the challenge day. Analyses were conducted on the maximal change score from the baseline measurement for each variable. Overall, there were no main effects or interactions involving   FIG. 2 . Activation map for the increasing working memory load contrast form the N-back task on the placebo challenge day (P < 0.005). The N-back task activated the expected bilateral frontal, parietal, and cerebellar regions during the placebo challenge day. Orange colors represent regions where the activation is increasing as the working memory load (N) increases. Blue colors represent activation that is decreasing as the N increases. Blood samples were obtained for hormone assays at the beginning of each study day before any other study procedures. As expected, we found no differences in estrone, estradiol, or testosterone values across the three drug challenge days.
DISCUSSION
The current study was the first to examine the working memory-related functional brain circuitry affected by direct dopaminergic stimulation and blockade in postmenopausal women. The results showed that the D 2 agonist BROMO increased brain activation primarily in posterior regions of the working memory network compared with the antagonist HAL. In addition, the post hoc analysis of the two medications separately compared with PLC showed that the increased activation seemed to be driven by BROMO rather than HAL. Neither BROMO nor HAL, however, affected working memory performance. These findings highlight that the dopaminergic system is responsive to manipulations in healthy postmenopausal women and emphasize the need for further studies to examine how these brain activation effects may influence cognition and behavior.
We hypothesized that dopaminergic stimulation would increase frontal lobe activation and improve performance in postmenopausal women. The data showed that activation was increased after BROMO compared with HAL in posterior regions of the working memory network, but not in the frontal regions as predicted. In addition, there were no effects of either medication on performance. Prior studies using BROMO to examine N-back activation during fMRI found decreased frontal activation and improved performance, but the participants were younger and the samples were mixed with regard to sex. 28, 48 Thus, perhaps sex and menopause status affect the BOLD signal after dopaminergic manipulations, and these effects are observed in more posterior working memory regions. fMRI studies of working memory in postmenopausal women during estrogen treatment 26 have also shown increased BOLD activation. Studies examining estrogen compared with PLC treatment in postmenopausal women found increased frontal activation and no effect on performance during working memory tasks. 27, 49, 50 Although the prior studies of estrogen treatment and fMRI differ with 
FIG. 4. Sensitivity (d') (A), proportion correct (B)
, and bias (C) (C) with standard errors on the 0-, 1-, 2-, and 3-back conditions on the bromocriptine, haloperidol, and placebo challenge days. BROMO, bromocriptine; HAL, haloperidol; PLC, placebo.
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regard to design, hormone treatments, and neuropsychological tests, it seems that an increase in the BOLD signal measured during fMRI is common across estrogen treatment studies. 26 Our dopaminergic manipulation also showed an increase in BOLD signal during the stimulation compared with the blockade condition although it was in parietal and posterior frontal regions. This pattern of results leads to the hypothesis that dopaminergic stimulation may have similar effects on brain functioning as estrogen treatment in postmenopausal women.
Epperson et al 24, 51 have used a dopamine stimulation method to examine effects on subjective and objective cognitive performance in peri-and postmenopausal women in two studies. They found that atomoxetine treatment for 6 weeks compared with PLC improved subjective reports of memory and attention, but had no effect on objective performance. 24 They also found lisdexamphetamine for 4 weeks compared with PLC improved subjective cognition as well as delayed recall in postmenopausal women with menopause-related subjective cognitive decline. Thus, studies are beginning to examine methods other than hormonal treatment after menopause to affect brain functioning and methods that affect the dopaminergic system may be useful in this endeavor. Further work is, however, needed to examine the relationship of the increased BOLD signal found in the current study as well as improved subjective cognition found in Epperson et al 24 to objective cognitive performance in postmenopausal women.
There are some caveats about the current study that should be considered when interpreting these data. First, we did not find any effect of BROMO or HAL on working memory performance. Prior studies have also found minimal effects of the 1.25 mg dose of BROMO on cognitive performance, but similarly observed effects on brain activation. 28, 48, 52 Furthermore, we chose a low dose of HAL in our healthy participants so as to not produce excessive side effects, and we may not have observed any effects of HAL on its own as a result. In addition, HAL at higher doses has a less specific pharmacologic profile. It has been advised that modest doses are used in pharmacological imaging to avoid confounds of task-specific effects of drugs with secondary influences of altered arousal or other systemic effects. 53 Our examination of vital signs, mood, and behavioral measures indicated that our fMRI findings were not affected by these variables. A larger dose of the medications may, however, reveal BROMO and/or HAL effects on working memory performance.
Our sample size was small, and thus affected our ability to use the most conservative correction for multiple comparisons in the imaging analysis. We were not able to correct at the family wise error level for the whole brain analysis. We believe the whole brain analysis was necessary to examine the influence of direct dopaminergic modulation effects on working memory-related brain networks in postmenopausal women which had not yet been examined. We did use a cluster-level correction in this initial study of dopaminergic modulation of working memory in postmenopausal women. Thus, we take these data patterns to be suggestive of the functioning of the dopaminergic system in postmenopausal women, and the relationship between dopaminergic functioning and cognitive performance warrants further study with larger samples.
CONCLUSIONS
Overall, these data showed that a dopaminergic agonist increased posterior activation during a working memory task in healthy postmenopausal women compared with a dopaminergic antagonist. Performance was, however, not affected by the medication challenges. We propose that although the functioning of the dopaminergic system is influenced by circulating estrogen before menopause, dopaminergic system functioning was still modifiable after menopause in our sample. The structural 19, 20 as well as functional 54 changes in the dopaminergic system continue into older age. In early postmenopause, the dopaminergic system, however, seems to continue to respond to pharmacologic manipulations. Further studies are needed to determine whether and what kind of dopaminergic manipulation may benefit cognition in healthy postmenopausal aging.
